Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection

被引:46
作者
Habermehl, Daniel [1 ]
Brecht, Ingo C. [1 ]
Bergmann, Frank [2 ]
Welzel, Thomas [1 ]
Rieken, Stefan [1 ]
Werner, Jens [3 ]
Schirmacher, Peter [2 ]
Buechler, Markus W. [3 ]
Debus, Juergen [1 ]
Combs, Stephanie E. [1 ]
机构
[1] Univ Heidelberg Hosp, Dept Radiat Oncol, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Inst Pathol, D-69120 Heidelberg, Germany
[3] Univ Heidelberg Hosp, Dept Visceral Surg, D-69120 Heidelberg, Germany
关键词
CURATIVE RESECTION; ADJUVANT CHEMOTHERAPY; GEMCITABINE; ADENOCARCINOMA; CHEMORADIOTHERAPY; RADIOTHERAPY; PATTERNS; AUTOPSY; RISK;
D O I
10.1186/1748-717X-8-27
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In the present retrospective analysis we analysed the therapeutic outcome of a set of patients, who were treated with chemoradiation (CRT) for recurrent pancreatic cancer (RPC) in a single institution. Patients and Methods: Forty-one patients had a history of primary resection for pancreatic cancer. In case of an unresectable recurrency patients were treated with CRT at our institution between 2002 and 2010 with a median dose of 48.4 Gy (range 39.6-54 Gy). Concurrent chemotherapy regimes included Gemcitabine (GEM) in 37/41 patients (90%) and Fluorouracil (FU) or Capecitabine (CAP) in 4/41 patients (10%). Patients were re-evaluated after CRT with computed tomography and/or explorative laparotomy. During re-resection or laparotomy 15 patients received an additional intraoperative radiotherapy (IORT) with a median dose of 15 Gy (range 12-15 Gy). Median age was 65 years (range 39-76 years) and there were 26 male and 15 female patients. Results: The median overall survival (mOS), local control (LC) and progression-free survival (PFS) were 16.1, 13.8 and 6.9 months respectively for all patients after the first day of CRT. Re-resection was possible in five patients (12%) and a complete remission (CR) as defined by tumor-free biopsy was seen in 6 patients (15%). When re-resection could be achieved after CRT mOS was improved to 28.3 months (n = 5 patients, 95%-CI 10.2 - 46.3 months). Patients receiving IORT had a significantly improved mOS compared to no IORT (p = 0.034). Fifteen patients (37%) experienced a local tumour progression and main site of distant metastasis was the liver (11 patients, 27%). Overall treatment-related toxicity was mild, grade III hematologic toxicity was observed in 11 patients (27%). Conclusion: In summary we observed a good therapeutic response with mild to moderate toxicity levels for CRT in RPC. Overall survival and PFS were clearly improved in case of induction of a complete remission (tumor-free biopsies) or after achieving a re-resection, thus providing a curative intended therapy even in case of disease recurrence.
引用
收藏
页数:7
相关论文
共 26 条
[1]   Prognostic factors in resected pancreatic adenocarcinoma: Analysis of actual 5-year survivors [J].
Cleary, SP ;
Gryfe, R ;
Guindi, M ;
Greig, P ;
Smith, L ;
Mackenzie, R ;
Strasberg, S ;
Hanna, S ;
Taylor, B ;
Langer, B ;
Gallinger, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2004, 198 (05) :722-731
[2]   FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer [J].
Conroy, Thierry ;
Desseigne, Francoise ;
Ychou, Marc ;
Bouche, Olivier ;
Guimbaud, Rosine ;
Becouarn, Yves ;
Adenis, Antoine ;
Raoul, Jean-Luc ;
Gourgou-Bourgade, Sophie ;
de la Fouchardiere, Christelle ;
Bennouna, Jaafar ;
Bachet, Jean-Baptiste ;
Khemissa-Akouz, Faiza ;
Pere-Verge, Denis ;
Delbaldo, Catherine ;
Assenat, Eric ;
Chauffert, Bruno ;
Michel, Pierre ;
Montoto-Grillot, Christine ;
Ducreux, Michel .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (19) :1817-1825
[3]   Most pancreatic cancer resections are R1 resections [J].
Esposito, Irene ;
Kleff, Joerg ;
Bergmann, Frank ;
Reiser, Caroline ;
Herpel, Esther ;
Friess, Helmut ;
Schirmacher, Peter ;
Buechler, Markus W. .
ANNALS OF SURGICAL ONCOLOGY, 2008, 15 (06) :1651-1660
[4]   Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages [J].
Gillen, Sonja ;
Schuster, Tibor ;
zum Bueschenfelde, Christian Meyer ;
Friess, Helmut ;
Kleeff, Joerg .
PLOS MEDICINE, 2010, 7 (04)
[5]  
Habermehl D, 2012, STRAHLENTHER ONKOL, V188, P795, DOI 10.1007/s00066-012-0099-y
[6]   Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer [J].
Habermehl, Daniel ;
Kessel, Kerstin ;
Welzel, Thomas ;
Hof, Holger ;
Abdollahi, Amir ;
Bergmann, Frank ;
Rieken, Stefan ;
Weitz, Juergen ;
Werner, Jens ;
Schirmacher, Peter ;
Buechler, Markus W. ;
Debus, Juergen ;
Combs, Stephanie E. .
RADIATION ONCOLOGY, 2012, 7
[7]   Multivisceral Resection for Pancreatic Malignancies Risk-Analysis and Long-Term Outcome [J].
Hartwig, Werner ;
Hackert, Thilo ;
Hinz, Ulf ;
Hassenpflug, Matthias ;
Strobel, Oliver ;
Buechler, Markus W. ;
Werner, Jens .
ANNALS OF SURGERY, 2009, 250 (01) :81-87
[8]   Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings [J].
Hishinuma, S ;
Ogata, Y ;
Tomikawa, M ;
Ozawa, I ;
Hirabayashi, K ;
Igarashi, S .
JOURNAL OF GASTROINTESTINAL SURGERY, 2006, 10 (04) :511-518
[9]   Long-term results of full-dose gemcitabine with radiation therapy compared to 5-fluorouracil with radiation therapy for locally advanced pancreas cancer [J].
Huang, Jiayi ;
Robertson, John M. ;
Margolis, Jeffrey ;
Balaraman, Savitha ;
Gustafson, Gary ;
Khilanani, Prem ;
Nadeau, Laura ;
Jury, Robert ;
McIntosh, Bruce .
RADIOTHERAPY AND ONCOLOGY, 2011, 99 (02) :114-119
[10]  
KAYAHARA M, 1993, CANCER, V72, P2118, DOI 10.1002/1097-0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO